Last update 01 Nov 2024

TAB014

Overview

Basic Info

Drug Type
Recombinant protein
Synonyms
TAB014 monoclonal antibody injection
+ [1]
Target
VEGF
Mechanism
VEGF inhibitors(Vascular endothelial growth factor inhibitors)
Therapeutic Areas
Congenital DisordersEye Diseases
Active Indication
Wet age-related macular degeneration
Inactive Indication
Glycogen Storage Disease Type II
Originator Organization
TOT BIOPHARM International Co. Ltd.TOT BIOPHARM International Co. Ltd.
Active Organization
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.TOT BIOPHARM International Co. Ltd.TOT BIOPHARM International Co. Ltd.Tot Biopharm Co. Ltd.Tot Biopharm Co. Ltd.
Inactive Organization
Lee's Pharmaceutical Holdings Ltd.Lee's Pharmaceutical Holdings Ltd.
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Related

4
Clinical Trials associated with TAB014
NCT05461339 / RecruitingPhase 3
A Phase III, Randomized, Multicenter, Doubled-blind Clinical Trial Comparing the Efficacy and Safety of TAB014 and Lucentis in Neovascular Age-related Macular Degeneration (nAMD) Patients
CTR20211015 / Active, not recruitingPhase 3
评价TAB014对比雷珠单抗（诺适得®）在新生血管性年龄相关性黄斑变性患者中有效性和安全性的多中心、随机、双盲的III期临床研究
[Translation] A multicenter, randomized, double-blind Phase III clinical study to evaluate the efficacy and safety of TAB014 versus ranibizumab (Lucentis®) in patients with neovascular age-related macular degeneration
CTR20180360 / CompletedPhase 1
TAB014治疗湿性(新生血管性)年龄相关性黄斑变性（AMD）的I期临床研究
[Translation] Phase I clinical study of TAB014 for the treatment of wet (neovascular) age-related macular degeneration (AMD)
100 Clinical Results associated with TAB014
Login to view more data
100 Translational Medicine associated with TAB014
Login to view more data
100 Patents (Medical) associated with TAB014
Login to view more data
100 Deals associated with TAB014
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Wet age-related macular degenerationPhase 3
US
Tot Biopharm Co. Ltd.Tot Biopharm Co. Ltd.
12 May 2022
Glycogen Storage Disease Type IIPhase 2
CN
Lee's Pharmaceutical Holdings Ltd.Lee's Pharmaceutical Holdings Ltd.
15 Jun 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free